[Zhou Jun] the price of anticancer drugs has been reduced by 56%, which costs 2 billion yuan in half a year, to praise the motherland. When the battle of 4 + 7 expansion ends, how happy and how worried

This week saw the end of the battle of 1.4 + 7 expansion, how much joy and how much sorrow; 2 The price of anticancer drugs was reduced by 56%, which cost 2 billion in half a year, to praise the motherland; 3 The bottom price was exposed, and the national unified price of drugs is just around the corner; 4 Fuhong Hanlin Hong Kong stock was listed, and the battle of 4 + 7 expansion was over, how much joy and how much sorrow At noon on September 25, Shanghai Sunshine procurement platform announced the "publicity of the results of the proposed selection of drug centralized procurement in the alliance region", which attached the corresponding supply and supply provinces (regions) of the winning enterprises There are 77 enterprises in the alliance procurement, 45 enterprises to be selected and 60 products to be selected Compared with the lowest purchase price in 2018 in the alliance region, the average price to be selected will be reduced by 59%; compared with the price level of "4 + 7" pilot, the average price will be reduced by 25% It is not difficult to see several points in the purchase of the alliance: 1 The more the price is, the lower the price is Amlodipine has 11 over evaluated products, which are the most over evaluated varieties Compared with the first 4 + 7 volume purchase in December last year, the price is reduced by 60% at most, and there are many similar products Therefore, it can be seen that the more varieties have been evaluated, the greater the reduction in the bid price, and the more fierce the competition According to statistics, the average reduction of three or more varieties has reached 38%; the average reduction of three or less varieties has only been 4.52%, which fully confirms this point 2 The remaining 30% - 50% of the market of the bid winning enterprises According to the purchase rules published in the centralized document of drug purchase in the alliance region on September 1, the agreed purchase quantity of 25 selected varieties in the first year is displayed in the proportion of 50%, 60% and 70% The bid winning enterprises can still compete for the remaining 30% - 50% of the market But it also makes people ponder whether the price of finished drugs is decreasing, whether the price of API is also decreasing, and if not, whether it means that API is the biggest winner In principle, the rising price of finished drugs does not affect any API manufacturers No matter how the price of finished drugs drops, there will not be too much deviation in the total market demand of drugs (you can't take double drugs if you are ill) Therefore, whether the price of APIs is reduced during the centralized purchase is the key to reduce the cost of the winning enterprises The State Health Commission stressed that the situation of winning the bid was dead In September 26th, the news conference of the 70th anniversary activity of the founding of new China was held Ma Xiaowei, director of the national health and Health Committee, answered the questions of journalists During the period, it was emphasized that the national pharmaceutical reform and development stressed the need to strengthen and improve drug policies Such is the expansion and promotion of "4 + 7" bidding procurement The State Council and relevant departments have also taken effective measures to promote this reform It can even be said that it is an important breakthrough in the reform in recent years The first measure is to reduce the price of imported patented drugs Through national negotiations, 17 kinds of anti-cancer drugs will be reduced to enter the medical insurance The second is "4 + 7" centralized bidding and volume procurement Reduce the transaction cost, especially the cost of the intermediate link To solve the problem of inflated drug prices involves the pharmaceutical industry and the medical service industry A good solution to the problems will play a very important role in promoting the strategic restructuring and healthy competition of China's pharmaceutical industry, as well as in strengthening hospital management, standardizing medical behaviors, improving medical ethics and medical ethics At the same time, we should make all kinds of public hospitals at all levels actively use the winning drugs, organize the production and distribution of drugs, and avoid the situation of "winning the bid to die" Now, judging from the distribution and use of drugs, the progress is very good, and people can enjoy the dividend of drug price reduction Internet, chronic diseases and medical insurance price reduction will become a hot topic in the medical industry in 2019, and the state health insurance bureau will frequently state that a national medical insurance catalog and unified payment standard are on the way When internet medical treatment is implemented, chronic disease will be the first area to be attacked On September 20, the state health insurance bureau issued a notice on strengthening the construction of the style of medical security system In the positive innovation of government service, we mentioned that we should speed up the construction of a unified national medical insurance information system, actively promote "Internet plus medical insurance", push all the government service matters of medical security to the Internet and mobile terminals, and achieve "online operation" and "palm management" All kinds of signs show that online medical treatment and drug purchase reimbursement are close to us In the view of many doctors, the internet medical service is the most promising way to carry out the follow-up service, and most of the patients are chronic patients Because of the characteristics of chronic diseases, patients are most worried about going to and from the hospital It's not scientific and efficient to go to the hospital just to get the medicine and go to the hospital for registration There are 4 billion regular outpatient clinics in the country every 7 billion times They are most concerned about how to purchase drugs in a convenient follow-up visit Therefore, it is not difficult to predict that hypertension, diabetes, heart disease, etc., led by chronic diseases, are expected to become the first breakthrough for online medical treatment and medical insurance reimbursement Under the leadership of the government and the promotion of various forces, once the online and offline communication of chronic disease follow-up, the new channel is undoubtedly a blue ocean With the further expansion of the reimbursement scope, the online medical market for hypertension and diabetes will show a blowout growth Anticancer drugs are getting more attention -- worthy of being the "son" of the pharmaceutical industry On September 23, the official website of the national health and Health Commission issued the notice on printing and distributing the health China action cancer prevention and control implementation plan (2019-2022) It is emphasized that the cancer prevention and control system needs further improvement, and the comprehensive prevention and control of risk factors should be progressed The incidence rate of cancer and the trend of death rate must be checked The main contents are as follows: 1 Improve the accessibility of anticancer drugs To establish and improve the clinical comprehensive evaluation system of anticancer drugs Accelerate the registration and approval of new anticancer drugs at home and abroad, promote the simultaneous listing of new drugs at home and abroad, and unblock the temporary import channels of clinically urgent anticancer drugs Improve the accessibility of anticancer drugs To establish and improve the clinical comprehensive evaluation system of anticancer drugs Accelerate the registration and approval of new anticancer drugs at home and abroad, promote the simultaneous listing of new drugs at home and abroad, unblock the temporary import channels of clinically urgent anticancer drugs, and promote the replacement of generic drugs with clinically urgent, necessary and large amount and heavy drug burden In addition, it also emphasizes to accelerate the review and approval process of domestic HPV vaccine; accelerate the registration and approval of new anti-cancer drugs at home and abroad, promote the simultaneous listing of new drugs at home and abroad, unblock the temporary import channels of anti-cancer drugs urgently needed in clinical; improve the prevention and control ability of cancer traditional Chinese medicine; promote the anti-cancer and anti-cancer work in the workplace, etc In this way, to build a health industry cluster with cancer prevention as the core, supported by the integrated development of industry, University, research and use, supported by the construction of regional cancer prevention and control center, and comprehensively promote the docking and integration of medical services, health management and other fields will be the key content of the next National Cancer Center The price of anticancer drugs has been reduced by 56% and the cost for half a year is 2 billion yuan Praise for the motherland was released by the State Medical Insurance Bureau on 25th, saying that from January to June 2019, 318200 person times and 1.963 billion yuan were reimbursed for anticancer drugs negotiated by 17 kinds of national medical insurance The state health insurance bureau will continue to promote the national health insurance negotiation on the allocation and use of anticancer drugs in medical institutions, and safeguard the rights and interests of cancer patients Among the 17 kinds of drugs, including 12 solid tumor drugs and 5 blood tumor drugs, they are all clinically necessary, effective and urgently needed by the insured Compared with the average retail price, the payment standard of negotiated drugs decreased by 56.7% on average The price reduction is so large and the cost is so great It is not about the gain or loss of personal interests It is the state's efforts to effectively ensure that domestic cancer patients can get the proper treatment and effectively ensure the basic rights and interests of cancer patients The state health insurance bureau also said that in the future, it will continue to promote the allocation and use of anticancer drugs in medical institutions under the national health insurance negotiation, establish a dynamic adjustment mechanism of the medical insurance catalog, and strive to achieve the goal of more optimized drug structure, more standardized management, and more efficient use of medical insurance funds, so as to further improve the level of drug security, including anticancer drugs All this is to serve the people and praise the motherland After the exposure of the industry's hot news base price, the national unified price of drugs will be around the corner on September 24, Qinghai Province released the notice on publishing the results of filling in the national lowest price enterprises of some drugs, which publicized the national lowest price of some drugs that enterprises were required to fill in the previous period The number of drugs to be filled in this time is 523, and 25 product sequences are not filled in It is worth noting that the list includes 122 key monitoring products, that is to say, the national lowest price of 122 key monitoring drugs is publicized to the public, so as to indirectly guide other provinces' purchase platforms, and carry out drug price reduction policies and drug regulatory functions based on this In my opinion, this quotation in Jiangxi Province is undoubtedly to help enterprises to raise the bottom The government needs to make clear the specific profits of drugs, and the purpose of publicizing them to the whole country is obvious It is to let the people of the whole country supervise whether there are regional pricing differences among enterprises It is also to hope that other provinces can follow similar behaviors, and provide reference with this price, which seems to be overbearing, but it is the goal The most effective way to reduce the price of drugs before In the future, once the national drug price becomes transparent, it will be clear what kind of drug is and how much, and the national unified retail price of nongfushanquan version will no longer be far away, which is not only conducive to the people's access to low-cost drugs, improving people's happiness, but also conducive to the state's supervision of drug price (price deviation, it will be easy to know once checked), and the Tianwang system of the pharmaceutical industry will be formal It's online The premier once again stressed that pharmaceutical enterprises should learn to "think what the country thinks and do what the country does" On September 20, Premier Li Keqiang visited Harbin Pharmaceutical Group Bioengineering Co., Ltd to understand whether the drug price, production and research and development, tax reduction and fee reduction are in place In the preparation workshop, premier inspected the pharmaceutical production process It is emphasized once again that the measures to strengthen the supply guarantee and stabilize the price of commonly used drugs are aimed at ensuring the drug demand of the masses and reducing the burden The supply demand of basic drugs is related to the life and health safety of the people and should not be underestimated However, many enterprises have also said that: Nowadays, the medical environment is sluggish, and the price of drugs is so low The prices of some drugs have not changed even in the past 10 years, but the prices are increasing again and again (pork is 20-30 / Jin), and even many drugs are not profitable or even negative The premier pointed out that: drugs are special commodities Pharmaceutical enterprises should not only achieve good operation, but also undertake certain social responsibilities to ensure the normal supply of basic drugs and other commonly used drugs This can not only meet the needs of the people, but also win a bigger market for the future development of enterprises "For the imported drugs urgently needed by the people, we need to further dredge channels and import them This is not only to comply with the wishes of the masses of the people, but also to force the upgrading of domestic related industries " Combined with the prime minister's words, I believe that the prime minister emphasizes that pharmaceutical manufacturers should take the initiative to ensure the supply of basic drugs while strengthening drug R & D and innovation, so as to meet the demand of the market It's not advisable to pursue profits and trade costs If enterprises want to go further, what they want to do must conform to the national health industry strategic plan Country of thought